New combo therapy aims to boost lung cancer treatment
NCT ID NCT05937906
First seen Jun 27, 2026 · Last updated Jul 10, 2026 · Updated 2 times
Summary
This study tests whether adding a short course of a MEK inhibitor (mirdametinib) to standard chemoimmunotherapy is safe and effective for people with advanced non-squamous non-small cell lung cancer that has low PDL1 levels. The trial has two parts: first finding the best dose, then comparing the new combination to standard treatment in 24 participants. The goal is to improve disease control without increasing side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC NON-SQUAMOUS NON-SMALL CELL LUNG ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Centre Georges-François Leclerc
RECRUITINGDijon, Burgundy, 21000, France
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a new immunotherapy combo outsmart advanced lung cancer?
- Double attack on mutant KRAS: can two targeted drugs outsmart resistant cancers?
- Seeing the fight: new imaging tracer may reveal how immune cells attack lung cancer
- Could a bronchial wash detect lung cancer mutations faster?
- Can a targeted pill outsmart a tough lung cancer mutation?
- Can a PET scan reveal hidden heart harm from lung cancer treatment?